Argenx’s first acquisition is the buyout of Forte Biosciences, a company with a lead drug that has early clinical validation in celiac disease and vitiligo. Argenx executives say this antibody complements its blockbuster product Vyvgart, offering a different mechanism of action but similar pipeline-in-a-product potential.

The post Argenx’s $2B Forte Bio Acquisition Brings Autoimmune Playbook to Prevalent Disorders appeared first on MedCity News.